Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2018-02-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1719760115PMID 29434041PMCID PMC5828621
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

  2017cited by this paper
• PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis

  2017cited by this paper
• Aneuploidy Causes Non-genetic Individuality.

  2017cited by this paper
• The polo-like kinase 4 gene (PLK4) is overexpressed in pediatric medulloblastoma

  2017cited by this paper
• A functional screening of the kinome identifies the Polo‐like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain

  2017cited by this paper
• Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer

  2017influential reference
• Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].

  2016cited by this paper
• Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts

  2016cited by this paper
• Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2

  2016cited by this paper
• Lung Cancer Statistics.

  2016cited by this paper
• Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

  2015cited by this paper
• Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown

  2015cited by this paper
• Global cancer statistics, 2012

  2015cited by this paper
• The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

  2015cited by this paper
• Drug discovery using spirooxindole cores: Success and Challenges [corrected].

  2015cited by this paper
• Global trends of lung cancer mortality and smoking prevalence.

  2015cited by this paper
• CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.

  2015cited by this paper
• Global Cancer Incidence and Mortality Rates and Trends—An Update

  2015cited by this paper
• The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

  2015cited by this paper
• Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

  2014influential reference
• KRAS mutation: should we test for it, and does it matter?

  2013cited by this paper
• Anaphase Catastrophe Is a Target for Cancer Therapy

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention

  2010cited by this paper
• Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe

  2010influential reference
• MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors.

  2010cited by this paper
• Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability

  2010cited by this paper
• Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression.

  2009cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• A Mechanism Linking Extra Centrosomes to Chromosomal Instability

  2009cited by this paper
• Multipolar Spindle Pole Coalescence Is a Major Source of Kinetochore Mis-Attachment and Chromosome Mis-Segregation in Cancer Cells

  2009cited by this paper
• Centrosome amplification can initiate tumorigenesis in flies.

  2008cited by this paper
• Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes.

  2008cited by this paper
• Plk4-induced centriole biogenesis in human cells.

  2007cited by this paper
• Overexpressing Centriole-Replication Proteins In Vivo Induces Centriole Overduplication and De Novo Formation

  2007cited by this paper
• Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas

  2007cited by this paper
• Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations

  2007cited by this paper
• K-ras mutations in non-small-cell lung carcinoma: a review.

  2006cited by this paper
• High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.

  2006cited by this paper
• Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• RNA-dependent integrin α3 protein localization regulated by the Muscleblind-like protein MLP1

  2005cited by this paper
• The Polo kinase Plk4 functions in centriole duplication

  2005cited by this paper
• SAK/PLK4 is required for centriole duplication and flagella development.

  2005cited by this paper
• Polo-like kinases and the orchestration of cell division

  2004cited by this paper
• Aneuploidy and cancer

  2004cited by this paper
• Centrosome amplification drives chromosomal instability in breast tumor development

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Centrosome aberrations: cause or consequence of cancer progression?

  2002cited by this paper
• Comparative Expression of the Mitotic Regulators SAK and PLK in Colorectal Cancer

  2001cited by this paper
• Aneuploidy and cancer

  2000cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference

• PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity

  2025influential citation
• Discovery of Potent, Selective and Efficacious Aminopyrazole Inhibitors of PLK4.

  2025cites this paper
• Polo-like kinase 4: A molecular linchpin in cancer and its management

  2025influential citation
• Senolytic Elimination of Senescent Ovarian Clear Cell Carcinoma Cells Induced by CEP-1347 With the BH3 Mimetic Navitoclax

  2025cites this paper
• Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer

  2025cites this paper
• Rational design of CZL-S092: A novel indazole-based PLK4 inhibitor targeting neuroblastoma through virtual screening and fragment-based drug design strategies.

  2025cites this paper
• Role of PLK4 inhibition in cancer therapy

  2025cites this paper
• PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.

  2025cites this paper
• PLK4: Master Regulator of Centriole Duplication and Its Therapeutic Potential

  2025cites this paper
• CDK2 inhibition produces a persistent population of polyploid cancer cells

  2025cites this paper
• Tetraploidy in normal tissues and diseases: mechanisms and consequences

  2025cites this paper
• Harnessing Structure Prediction of Polo‐Like Kinase 4 for Drug Repurposing

  2025cites this paper
• Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification

  2024cites this paper
• Polo-like kinase 4 accelerates glioma malignant progression and vasculogenic mimicry by phosphorylating EphA2.

  2024cites this paper
• Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma

  2024cites this paper
• Design of novel PLK4 inhibitors as TRIM37-amplified breast cancer drugs using 3D-QSAR, molecular docking, and molecular dynamics simulation methods

  2024cites this paper
• The two sides of chromosomal instability: drivers and brakes in cancer

  2024cites this paper
• Polyploidy in Cancer: causal mechanisms, cancer-specific consequences, and emerging treatments.

  2024cites this paper
• Therapeutic potential of targeting polo-like kinase 4.

  2024cites this paper
• A comprehensive review on the indazole based derivatives as targeted anticancer agents

  2023cites this paper
• Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms

  2023cites this paper
• CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells

  2023cites this paper
• Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML.

  2023cites this paper
• PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/β-catenin pathway in anaplastic thyroid cancer

  2023cites this paper
• Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

  2023cites this paper
• Polo-like kinase 4 inhibitor CFI-400945 inhibits carotid arterial neointima formation but increases atherosclerosis

  2023influential citation
• Polo‐like kinase 4 inhibitor CFI‐400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity

  2022cites this paper
• Design, synthesis, and biological evaluation of a potent PLK4 inhibitor WY29 with 1H‐pyrazolo[3,4‐d]pyrimidine scaffold

  2022cites this paper
• PLK4 Is a Potential Biomarker for Abnormal Tumor Proliferation, Immune Infiltration, and Prognosis in ccRCC

  2022cites this paper
• Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.

  2022cites this paper
• Effects of the PLK4 inhibitor Centrinone on the biological behaviors of acute myeloid leukemia cell lines

  2022cites this paper
• Anticancer Effects and Mechanisms of CFI-400945 and Radiation in Breast Cancer

  2022cites this paper
• Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.

  2022cites this paper
• A Selective β−Catenin‐Metadherin/CEACAM1‐CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor–Macrophage Interaction

  2022cites this paper
• Keep Calm and Carry on with Extra Centrosomes

  2022cites this paper
• Repair of Spinal Cord Injury by Inhibition of PLK4 Expression Through Local Delivery of siRNA-Loaded Nanoparticles

  2021cites this paper
• Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management

  2021cites this paper
• Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy

  2021cites this paper
• Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer

  2021cites this paper
• Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

  2021cites this paper
• Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma

  2021cites this paper
• Down‐regulation of Polo‐like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signaling pathway in bladder cancer

  2021cites this paper
• TEC kinase stabilizes PLK4 to promote liver cancer metastasis.

  2021cites this paper
• Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4

  2021cites this paper
• Investigating the Functions of PLK4 in Epigenetic Regulation

  2021cites this paper
• YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects

  2020cites this paper
• Activating transcription factor 6 (ATF6) negatively regulates Polo-like kinase 4 expression via recruiting C/EBPβ to the upstream-promoter during ER stress.

  2020cites this paper
• A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

  2020cites this paper
• Gene expression profile of lipopolysaccharide-induced apoptosis of nucleus pulposus cells reversed by syringic acid

  2020cites this paper
• Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant

  2020cites this paper
• OTT_A_258616 7997..8008

  2020cites this paper
• Non-mitotic functions of polo-like kinases in cancer cells.

  2020cites this paper
• Cancer predictive studies

  2020cites this paper
• Exploiting TRIM37-driven centrosome dysfunction to kill breast cancer cells

  2020cites this paper
• Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer

  2020cites this paper
• Identification of compounds that bind the centriolar protein SAS-6 and inhibit its oligomerization

  2020cites this paper
• MiR-654-3p Suppresses Non-Small Cell Lung Cancer Tumourigenesis by Inhibiting PLK4

  2020cites this paper
• Cancer regeneration: Polyploid cells are the key drivers of tumor progression.

  2020cites this paper
• FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity

  2020cites this paper
• Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion.

  2020cites this paper
• FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity

  2020cites this paper
• Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells

  2020cites this paper
• Screening and Identification of Therapeutic Targets for Pulmonary Arterial Hypertension Through Microarray Technology

  2020cites this paper
• TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.

  2020cites this paper
• Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer

  2020cites this paper
• Threonine Tyrosine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy

  2019cites this paper
• New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy.

  2019cites this paper
• Polo‐like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non‐small cell lung cancer

  2019cites this paper
• PLK4: a promising target for cancer therapy

  2019cites this paper
• Centrosome Amplification and Tumorigenesis: Cause or Effect?

  2019cites this paper
• Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy

  2019cites this paper
• Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

  2019cites this paper
• POLQ Overexpression Is Associated with an Increased Somatic Mutation Load and PLK4 Overexpression in Lung Adenocarcinoma

  2019cites this paper
• Role for polo-like kinase 4 in mediation of cytokinesis

  2019cites this paper
• Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors

  2019cites this paper
• Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer

  2019influential citation
• Myricetin inhibits panel of kinases implicated in tumorigenesis

  2019cites this paper
• PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.

  2019cites this paper
• Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

  2018cites this paper
• Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB)

  2018cites this paper
• CFI-400945 is not a selective cellular PLK4 inhibitor

  2018cites this paper
• Targeting the cell cycle in breast cancer: towards the next phase

  2018cites this paper
• High PLK4 expression promotes tumor progression and induces epithelial-mesenchymal transition by regulating the Wnt/β-catenin signaling pathway in colorectal cancer

  2018cites this paper
• Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition

  2018cites this paper